Emerging nanotechnology approaches for HIV/AIDS treatment and prevention

Bibliography

• 1  Blattner W, Gallo RC, Temin HM: HIV causes AIDS. Science241(4865),515–516 (1988).
  Medline CASGoogle Scholar
• 2  Gallo RC: Historical essay. The early years of HIV/AIDS. Science298(5599),1728–1730 (2002).
  Medline CASGoogle Scholar
• 3  Gallo RC, Montagnier L: The discovery of HIV as the cause of AIDS. N. Engl. J. Med.349(24),2283–2285 (2003).
  Medline CASGoogle Scholar
• 4  Montagnier L: Historical essay. A history of HIV discovery. Science298(5599),1727–1728 (2002).
  Medline CASGoogle Scholar
• 5  Furin JJ, Behforouz HL, Shin SS et al.: Expanding global HIV treatment: Case studies from the field. Ann. NY Acad. Sci.1136,12–20 (2008).
  Medline CASGoogle Scholar
• 6  Merson MH: The HIV-AIDS pandemic at 25 – the global response. N. Engl J. Med.354(23),2414–2417 (2006).
  Medline CASGoogle Scholar
• 7  Joint United Nations Programme on HIV/AIDS: Report on the global HIV/AIDS epidemic. Joint United Nations Programme on HIV/AIDS. Geneva, Switzerland (2008).
  Google Scholar
• 8  Rodriguez-Monguio R, Seoane-Vazquez E: Patent life of antiretroviral drugs approved in the US from 1987 to 2007. AIDS Care1–9 (2009).
  Google Scholar
• 9  Lang L: FDA grants tentative approval for 75th generic antiretroviral drug. Gastroenterology136(1),5 (2009).
  Google Scholar
• 10  Walensky RP, Paltiel AD, Losina E et al.: The survival benefits of AIDS treatment in the United States. J. Infect. Dis.194(1),11–19 (2006).
  MedlineGoogle Scholar
• 11  Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ: The challenge of finding a cure for HIV infection. Science323(5919),1304–1307 (2009).
  Medline CASGoogle Scholar
• 12  Richman DD: HIV chemotherapy. Nature410(6831),995–1001 (2001).
  Medline CASGoogle Scholar
• 13  Ledford H: Merck’s HIV vaccine flop brings vectors under closer scrutiny. Nat. Biotechnol.26(1),3–4 (2008).
  Medline CASGoogle Scholar
• 14  Ledford H: HIV vaccine developers battle on, despite high-profile failures. Nat. Biotechnol.26(6),591–592 (2008).
  Medline CASGoogle Scholar
• 15  Uberla K: HIV vaccine development in the aftermath of the step study: Re-focus on occult HIV infection? PLoS Pathog.4(8),e1000114 (2008).
  MedlineGoogle Scholar
• 16  Cohen J: Aids research. Microbicide fails to protect against HIV. Science319(5866),1026–1027 (2008).
  Medline CASGoogle Scholar
• 17  Grant RM, Hamer D, Hope T et al.: Whither or wither microbicides? Science321(5888),532–534 (2008).
  Medline CASGoogle Scholar
• 18  Farokhzad OC: Nanotechnology for drug delivery: The perfect partnership. Expert Opin. Drug Deliv.5(9),927–929 (2008).
  Medline CASGoogle Scholar
• 19  Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC: Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther.83(5),761–769 (2008).
  Medline CASGoogle Scholar
• 20  Ferrari M: Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer5(3),161–171 (2005).
  Medline CASGoogle Scholar
• 21  Nie S, Xing Y, Kim GJ, Simons JW: Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng.9,257–288 (2007).
  Medline CASGoogle Scholar
• 22  Heath JR, Davis ME: Nanotechnology and cancer. Ann. Rev. Med.59,251–265 (2008).
  Medline CASGoogle Scholar
• 23  Harrigan PR, Hogg RS, Dong WW et al.: Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J. Infect. Dis.191(3),339–347 (2005).
  Medline CASGoogle Scholar
• 24  Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS: Re-emergence of HIV after stopping therapy. Nature401(6756),874–875 (1999).
  Medline CASGoogle Scholar
• 25  Marsden MD, Zack JA: Eradication of HIV: Current challenges and new directions. J. Antimicrob. Chemother.63(1),7–10 (2009).
  Medline CASGoogle Scholar
• 26  Sax PE, Cohen CJ, Kuritzkes DR: HIV Essentials. Physicians’ Press, Royal Oak, MI, USA (2007).
  Google Scholar
• 27  Lamers SL, Salemi M, Galligan DC et al.: Extensive HIV-1 intra-host recombination is common in tissues with abnormal histopathology. PLoS One4(3),E5065 (2009).
  MedlineGoogle Scholar
• 28  McGee B, Smith N, Aweeka F: HIV pharmacology: Barriers to the eradication of HIV from the CNS. HIV Clin. Trials7(3),142–153 (2006).
  MedlineGoogle Scholar
• 29  Vyas TK, Shah L, Amiji MM: Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin. Drug Deliv.3(5),613–628 (2006).
  Medline CASGoogle Scholar
• 30  Wan L, Pooyan S, Hu P, Leibowitz MJ, Stein S, Sinko PJ: Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted peg-fmlf (n-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery. Pharm. Res.24(11),2110–2119 (2007).
  Medline CASGoogle Scholar
• 31  Nowacek A, Gendelman HE: Nanoart, neuroAIDS and CNS drug delivery. Nanomed.4(5),557–574 (2009).
  CASGoogle Scholar
• 32  Farokhzad OC, Langer R: Impact of nanotechnology on drug delivery. ACS Nano3(1),16–20 (2009).
  Medline CASGoogle Scholar
• 33  Davis ME, Chen ZG, Shin DM: Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov.7(9),771–782 (2008).
  Medline CASGoogle Scholar
• 34  Amiji MM, Vyas TK, Shah LK: Role of nanotechnology in HIV/AIDS treatment: Potential to overcome the viral reservoir challenge. Discov. Med.6(34),157–162 (2006).
  MedlineGoogle Scholar
• 35  Baert L, van’t Klooster G, Dries W et al.: Development of a long-acting injectable formulation with nanoparticles of rilpivirine (tmc278) for HIV treatment. Eur. J. Pharm. Biopharm.72(3),502–508 (2009).
  Medline CASGoogle Scholar
• 36  Dou H, Destache CJ, Morehead JR et al.: Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood108(8),2827–2835 (2006).
  Medline CASGoogle Scholar
• 37  Dou H, Morehead J, Destache CJ et al.: Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology358(1),148–158 (2007).
  Medline CASGoogle Scholar
• 38  Dou H, Grotepas CB, McMillan JM et al.: Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol.183(1),661–669 (2009).
  Medline CASGoogle Scholar
• 39  Garg M, Asthana A, Agashe HB, Agrawal GP, Jain NK: Stavudine-loaded mannosylated liposomes: In-vitro anti-HIV-i activity, tissue distribution and pharmacokinetics. J. Pharm. Pharmacol.58(5),605–616 (2006).
  Medline CASGoogle Scholar
• 40  Garg M, Dutta T, Jain NK: Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. Eur. J. Pharm. Biopharm.67(1),76–85 (2007).
  Medline CASGoogle Scholar
• 41  Garg M, Garg BR, Jain S et al.: Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral efficacy of stavudine loaded 99mtc labeled galactosylated liposomes. Eur. J. Pharm. Sci.33(3),271–281 (2008).
  Medline CASGoogle Scholar
• 42  Kaur CD, Nahar M, Jain NK: Lymphatic targeting of zidovudine using surface-engineered liposomes. J. Drug Target16(10),798–805 (2008).
  Medline CASGoogle Scholar
• 43  Dutta T, Agashe HB, Garg M, Balakrishnan P, Kabra M, Jain NK: Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target15(1),89–98 (2007).
  Medline CASGoogle Scholar
• 44  Dutta T, Jain NK: Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta1770(4),681–686 (2007).
  Medline CASGoogle Scholar
• 45  Dutta T, Garg M, Jain NK: Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur. J. Pharm. Sci.34(2–3),181–189 (2008).
  Medline CASGoogle Scholar
• 46  Wan L, Zhang X, Pooyan S et al.: Optimizing size and copy number for PEG-FMLF (n-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages. Bioconjug. Chem.19(1),28–38 (2008).
  Medline CASGoogle Scholar
• 47  Ganser-Pornillos BK, Yeager M, Sundquist WI: The structural biology of HIV assembly. Curr. Opin. Struct. Biol.18(2),203–217 (2008).
  Medline CASGoogle Scholar
• 48  Pornillos O, Ganser-Pornillos BK, Kelly BN et al.: X-ray structures of the hexameric building block of the HIV capsid. Cell137(7),1282–1292 (2009).
  MedlineGoogle Scholar
• 49  Friedman SH, Decamp DL, Sijbesma RP, Srdanov G, Wudl F, Kenyon GL: Inhibition of the HIV-1 protease by fullerene derivatives – model-building studies and experimental-verification. J. Am. Chem. Soc.115(15),6506–6509 (1993).
  CASGoogle Scholar
• 50  Bosi S, Da Ros T, Spalluto G, Balzarini J, Prato M: Synthesis and anti-HIV properties of new water-soluble bis-functionalized[60]fullerene derivatives. Bioorg. Med. Chem. Lett.13(24),4437–4440 (2003).
  Medline CASGoogle Scholar
• 51  Kotelnikova RA, Bogdanov GN, Frog EC et al.: Nanobionics of pharmacologically active derivatives of fullerene c-60. J. Nanopart. Res.5(5–6),561–566 (2003).
  CASGoogle Scholar
• 52  Marchesan S, Da Ros T, Spalluto G, Balzarini J, Prato M: Anti-HIV properties of cationic fullerene derivatives. Bioorg. Med. Chem. Lett.15(15),3615–3618 (2005).
  Medline CASGoogle Scholar
• 53  Troshina OA, Troshin PA, Peregudov AS, Kozlovskiy VI, Balzarini J, Lyubovskaya RN: Chlorofullerene c60cl6: A precursor for straightforward preparation of highly water-soluble polycarboxylic fullerene derivatives active against HIV. Org. Biomol. Chem.5(17),2783–2791 (2007).
  Medline CASGoogle Scholar
• 54  Durdagi S, Supuran CT, Strom TA et al.: In silico drug screening approach for the design of magic bullets: A successful example with anti-HIV fullerene derivatized amino acids. J. Chem. Inf. Model49(5),1139–1143 (2009).
  Medline CASGoogle Scholar
• 55  Tanimoto S, Sakai S, Matsumura S, Takahashi D, Toshima K: Target-selective photo-degradation of HIV-1 protease by a fullerene–sugar hybrid. Chem. Commun. (44),5767–5769 (2008).
  MedlineGoogle Scholar
• 56  Blanzat M, Turrin CO, Aubertin AM et al.: Dendritic catanionic assemblies: In vitro anti-HIV activity of phosphorus-containing dendrimers bearing gal beta(1)cer analogues. Chembiochem.6(12),2207–2213 (2005).
  Medline CASGoogle Scholar
• 57  Wang W, Guo ZP, Chen Y, Liu T, Jiang L: Influence of generation 2–5 of pamam dendrimer on the inhibition of tat peptide/tar rna binding in HIV-1 transcription. Chem. Biol. Drug Des.68(6),314–318 (2006).
  Medline CASGoogle Scholar
• 58  Elechiguerra JL, Burt JL, Morones JR et al.: Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnology3,6 (2005).
  MedlineGoogle Scholar
• 59  Sun RW, Chen R, Chung NP, Ho CM, Lin CL, Che CM: Silver nanoparticles fabricated in hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem. Commun. (40),5059–5061 (2005).
  MedlineGoogle Scholar
• 60  Bowman MC, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C: Inhibition of HIV fusion with multivalent gold nanoparticles. J. Am. Chem. Soc.130(22),6896–6897 (2008).
  Medline CASGoogle Scholar
• 61  Rossi JJ, June CH, Kohn DB: Genetic therapies against HIV. Nat. Biotechnol.25(12),1444–1454 (2007).
  Medline CASGoogle Scholar
• 62  Haasnoot J, Westerhout EM, Berkhout B: Rna interference against viruses: strike and counterstrike. Nat. Biotechnol.25(12),1435–1443 (2007).
  Medline CASGoogle Scholar
• 63  Li M, Rossi JJ: Lentiviral vector delivery of siRNA and shrna encoding genes into cultured and primary hematopoietic cells. Methods Mol. Biol.433,287–299 (2008).
  Medline CASGoogle Scholar
• 64  Morris KV, Rossi JJ: Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther.13(6),553–558 (2006).
  Medline CASGoogle Scholar
• 65  Li M, Li H, Rossi JJ: RNAI in combination with a ribozyme and tar decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann. NY Acad. Sci.1082,172–179 (2006).
  Medline CASGoogle Scholar
• 66  Li MJ, Kim J, Li S et al.: Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shrna, anti-ccr5 ribozyme, and a nucleolar-localizing tar decoy. Mol. Ther.12(5),900–909 (2005).
  Medline CASGoogle Scholar
• 67  Lee SK, Dykxhoorn DM, Kumar P et al.: Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood106(3),818–826 (2005).
  Medline CASGoogle Scholar
• 68  Barnor JS, Miyano-Kurosaki N, Yamaguchi K, Abumi Y, Ishikawa K, Yamamoto N: Lentiviral-mediated delivery of combined HIV-1 decoy tar and VIF siRNA as a single rna molecule that cleaves to inhibit HIV-1 in transduced cells. Nucleosides Nucleotides Nucleic Acids24(5–7),431–434 (2005).
  Medline CASGoogle Scholar
• 69  Mitsuyasu RT, Merigan TC, Carr A et al.: Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34⁺ cells. Nat. Med.15(3),285–292 (2009).
  Medline CASGoogle Scholar
• 70  Mintzer MA, Simanek EE: Nonviral vectors for gene delivery. Chem. Rev.109(2),259–302 (2009).
  Medline CASGoogle Scholar
• 71  Lundin KE, Simonson OE, Moreno PM et al.: Nanotechnology approaches for gene transfer. Genetica137(1),47–56 (2009).
  Medline CASGoogle Scholar
• 72  Gao X, Kim KS, Liu DX: Nonviral gene delivery: What we know and what is next. AAPS J.9(1),E92–E104 (2007).
  Medline CASGoogle Scholar
• 73  Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature391(6669),806–811 (1998).
  Medline CASGoogle Scholar
• 74  Whitehead KA, Langer R, Anderson DG: Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov.8(2),129–138 (2009).
  Medline CASGoogle Scholar
• 75  Berkhout B, ter Brake O: Towards a durable rnai gene therapy for HIV-AIDS. Expert Opin. Biol. Ther.9(2),161–170 (2009).
  Medline CASGoogle Scholar
• 76  Davis ME: The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol. Pharm.6(3),659–668 (2009).
  Medline CASGoogle Scholar
• 77  Eguchi A, Meade BR, Chang YC et al.: Efficient siRNA delivery into primary cells by a peptide transduction domain-dsrna binding domain fusion protein. Nat. Biotechnol.27(6),567–571 (2009).
  Medline CASGoogle Scholar
• 78  Song E, Zhu P, Lee SK et al.: Antibody mediated in vivo delivery of small interfering rnas via cell-surface receptors. Nat. Biotechnol.23(6),709–717 (2005).
  Medline CASGoogle Scholar
• 79  Liu Z, Winters M, Holodniy M, Dai H: Sirna delivery into human t cells and primary cells with carbon-nanotube transporters. Angew. Chem. Int. Ed.46(12),2023–2027 (2007).
  Medline CASGoogle Scholar
• 80  Weber N, Ortega P, Clemente MI et al.: Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J. Control Release132(1),55–64 (2008).
  Medline CASGoogle Scholar
• 81  Kumar P, Ban HS, Kim SS et al.: T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell134(4),577–586 (2008).
  Medline CASGoogle Scholar
• 82  Kumar P, Wu HQ, McBride JL et al.: Transvascular delivery of small interfering RNA to the central nervous system. Nature448(7149),39–43 (2007).
  Medline CASGoogle Scholar
• 83  McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes B: The immune response during acute HIV-1 infection: Clues for vaccine development. Nat. Rev. Immunol. (2009).
  MedlineGoogle Scholar
• 84  Pett SL: Immunotherapies in HIV-1 infection. Curr. Opin. HIV AIDS4(3),188–193 (2009).
  MedlineGoogle Scholar
• 85  Gandhi RT, Walker BD: Immunologic control of HIV-1. Ann. Rev. Med.53,149–172 (2002).
  Medline CASGoogle Scholar
• 86  Cohen J: Building an HIV-proof immune system. Science317(5838),612–614 (2007).
  Medline CASGoogle Scholar
• 87  Rinaldo CR: Dendritic cell-based human immunodeficiency virus vaccine. J. Intern. Med.265(1),138–158 (2009).
  Medline CASGoogle Scholar
• 88  Banchereau J, Briere F, Caux C et al.: Immunobiology of dendritic cells. Ann. Rev. Immunol.18,767–811 (2000).
  Medline CASGoogle Scholar
• 89  Shortman K, Liu YJ: Mouse and human dendritic cell subtypes. Nat. Rev. Immunol.2(3),151–161 (2002).
  Medline CASGoogle Scholar
• 90  Bourinbaiar AS, Root-Bernstein RS, Abulafia-Lapid R et al.: Therapeutic AIDS vaccines. Curr. Pharm. Des.12(16),2017–2030 (2006).
  Medline CASGoogle Scholar
• 91  Dorrell L, Williams P, Suttill A et al.: Safety and tolerability of recombinant modified vaccinia virus ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine25(17),3277–3283 (2007).
  Medline CASGoogle Scholar
• 92  Gandhi RT, O’Neill D, Bosch RJ et al.: A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. Canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine27(43),6088–6094 (2009).
  Medline CASGoogle Scholar
• 93  Whiteside TL, Piazza P, Reiter A et al.: Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin. Vaccine Immunol.16(2),233–240 (2009).
  Medline CASGoogle Scholar
• 94  Tacken PJ, de Vries IJM, Torensma R, Figdor CG: Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat. Rev. Immunol.7(10),790–802 (2007).
  Medline CASGoogle Scholar
• 95  Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA: In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control Release112(1),26–34 (2006).
  Medline CASGoogle Scholar
• 96  Hori Y, Winans AM, Huang CC, Horrigan EM, Irvine DJ: Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. Biomaterials29(27),3671–3682 (2008).
  Medline CASGoogle Scholar
• 97  Elamanchili P, Diwan M, Cao M, Samuel J: Characterization of poly(d,l-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine22(19),2406–2412 (2004).
  Medline CASGoogle Scholar
• 98  Aline F, Brand D, Pierre J et al.: Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic pla nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine27(38),5284–5291 (2009).
  Medline CASGoogle Scholar
• 99  Lori F, Calarota SA, Lisziewicz J: Nanochemistry-based immunotherapy for HIV-1. Curr. Med. Chem.14(18),1911–1919 (2007).
  Medline CASGoogle Scholar
• 100  Bass E, Feuer C, Warren M: Aids vaccine research and advocacy: An update. BETA21(2),24–30 (2009).
  MedlineGoogle Scholar
• 101  Jefferys R: Vaccine failure is not a ‘crisis’ for HIV research. Nature453(7196),719–720 (2008).
  Medline CASGoogle Scholar
• 102  Barouch DH: Challenges in the development of an HIV-1 vaccine. Nature455(7213),613–619 (2008).
  Medline CASGoogle Scholar
• 103  Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S: Antigen presentation and t cell stimulation by dendritic cells. Ann. Rev. Immunol.20,621–667 (2002).
  Medline CASGoogle Scholar
• 104  Trombetta ES, Mellman I: Cell biology of antigen processing in vitro and in vivo. Ann. Rev. Immunol.23,975–1028 (2005).
  Medline CASGoogle Scholar
• 105  McHeyzer-Williams LJ, McHeyzer-Williams MG: Antigen-specific memory b cell development. Ann. Rev. Immunol.23,487–513 (2005).
  Medline CASGoogle Scholar
• 106  Fahmy TM, Demento SL, Caplan MJ, Mellman I, Saltzman WM: Design opportunities for actively targeted nanoparticle vaccines. Nanomed.3(3),343–355 (2008).
  CASGoogle Scholar
• 107  Csaba N, Garcia-Fuentes M, Alonso MJ: Nanoparticles for nasal vaccination. Adv. Drug Deliv. Rev.61(2),140–157 (2009).
  Medline CASGoogle Scholar
• 108  Sakaue G, Hiroi T, Nakagawa Y et al.: HIV mucosal vaccine: Nasal immunization with gp160-encapsulated hemagglutinating virus of japan-liposome induces antigen-specific ctls and neutralizing antibody responses. J. Immunol.170(1),495–502 (2003).
  Medline CASGoogle Scholar
• 109  Singh SK, Bisen PS: Adjuvanticity of stealth liposomes on the immunogenicity of synthetic gp41 epitope of HIV-1. Vaccine24(19),4161–4166 (2006).
  Medline CASGoogle Scholar
• 110  Wagner A, Stiegler G, Vorauer-Uhl K et al.: One step membrane incorporation of viral antigens as a vaccine candidate against HIV. J. Liposome Res.17(3–4),139–154 (2007).
  Medline CASGoogle Scholar
• 111  Watson DS, Huang Z, Szoka FC Jr: All-trans retinoic acid potentiates the antibody response in mice to a lipopeptide antigen adjuvanted with liposomal lipid a. Immunol. Cell Biol. (2009).
  MedlineGoogle Scholar
• 112  Letvin NL: Progress and obstacles in the development of an AIDS vaccine. Nat. Rev. Immunol.6(12),930–939 (2006).
  Medline CASGoogle Scholar
• 113  Burton DR, Desrosiers RC, Doms RW et al.: HIV vaccine design and the neutralizing antibody problem. Nat. Immunol.5(3),233–236 (2004).
  Medline CASGoogle Scholar
• 114  Takeda K, Kaisho T, Akira S: Toll-like receptors. Ann. Rev. Immunol.21,335–376 (2003).
  Medline CASGoogle Scholar
• 115  Fairman J, Moore J, Lemieux M et al.: Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum. Vaccin.5(2), (2008).
  Google Scholar
• 116  Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G: Mf59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol.6,277–296 (1995).
  Medline CASGoogle Scholar
• 117  Copland MJ, Rades T, Davies NM, Baird MA: Lipid based particulate formulations for the delivery of antigen. Immunol. Cell. Biol.83(2),97–105 (2005).
  Medline CASGoogle Scholar
• 118  Tritto E, Mosca F, De Gregorio E: Mechanism of action of licensed vaccine adjuvants. Vaccine27(25–26),3331–3334 (2009).
  Medline CASGoogle Scholar
• 119  Leung L, Srivastava IK, Kan E et al.: Immunogenicity of HIV-1 env and gag in baboons using a DNA prime/protein boost regimen. AIDS18(7),991–1001 (2004).
  Medline CASGoogle Scholar
• 120  Brave A, Hinkula J, Cafaro A et al.: Candidate HIV-1 gp140dv2, gag and tat vaccines protect against experimental HIV-1/MULV challenge. Vaccine25(39–40),6882–6890 (2007).
  MedlineGoogle Scholar
• 121  Burke B, Gomez-Roman VR, Lian Y et al.: Neutralizing antibody responses to subtype b and c adjuvanted HIV envelope protein vaccination in rabbits. Virology387(1),147–156 (2009).
  Medline CASGoogle Scholar
• 122  Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr: Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses24(2),271–281 (2008).
  Medline CASGoogle Scholar
• 123  Ataman-Onal Y, Munier S, Ganee A et al.: Surfactant-free anionic pla nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J. Control Release112(2),175–185 (2006).
  MedlineGoogle Scholar
• 124  Lamalle-Bernard D, Munier S, Compagnon C et al.: Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic pla nanoparticles preserves antigenicity and immunogenicity. J. Control Release115(1),57–67 (2006).
  Medline CASGoogle Scholar
• 125  Guillon C, Mayol K, Terrat C et al.: Formulation of HIV-1 tat and p24 antigens by pla nanoparticles or mf59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine25(43),7491–7501 (2007).
  Medline CASGoogle Scholar
• 126  Miyake A, Akagi T, Enose Y et al.: Induction of HIV-specific antibody response and protection against vaginal sHIV transmission by intranasal immunization with inactivated sHIV-capturing nanospheres in macaques. J. Med. Virol.73(3),368–377 (2004).
  Medline CASGoogle Scholar
• 127  Kawamura M, Wang X, Uto T et al.: Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice. J. Med. Virol.76(1),7–15 (2005).
  Medline CASGoogle Scholar
• 128  Akagi T, Wang X, Uto T, Baba M, Akashi M: Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials28(23),3427–3436 (2007).
  Medline CASGoogle Scholar
• 129  Wang X, Uto T, Akagi T, Akashi M, Baba M: Induction of potent CD8⁺ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. J. Virol.81(18),10009–10016 (2007).
  Medline CASGoogle Scholar
• 130  Wang X, Uto T, Akagi T, Akashi M, Baba M: Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: Potential for an AIDS vaccine. J. Med. Virol.80(1),11–19 (2008).
  Medline CASGoogle Scholar
• 131  Stoneburner RL, Low-Beer D: Population-level HIV declines and behavioral risk avoidance in uganda. Science304(5671),714–718 (2004).
  Medline CASGoogle Scholar
• 132  Rohan LC, Sassi AB: Vaginal drug delivery systems for HIV prevention. AAPS J.11(1),78–87 (2009).
  Medline CASGoogle Scholar
• 133  Saidi H: Microbicides: An emerging science of HIV-1 prevention in women-15th conference on retroviruses and opportunistic infections, boston, USA, 3–6 February 2008. Rev. Med. Virol.19(2),69–76 (2009).
  MedlineGoogle Scholar
• 134  das Neves J, Bahia MF: Gels as vaginal drug delivery systems. Int. J. Pharm.318(1–2),1–14 (2006).
  Medline CASGoogle Scholar
• 135  Klasse PJ, Shattock R, Moore JP: Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Ann. Rev. Med.59,455–471 (2008).
  Medline CASGoogle Scholar
• 136  Rupp R, Rosenthal SL, Stanberry LR: Vivagel (spl7013 gel): A candidate dendrimer – microbicide for the prevention of HIV and hsv infection. Int. J. Nanomedicine2(4),561–566 (2007).
  Medline CASGoogle Scholar
• 137  McCarthy TD, Karellas P, Henderson SA et al.: Dendrimers as drugs: Discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm.2(4),312–318 (2005).
  Medline CASGoogle Scholar
• 138  Jiang YH, Emau P, Cairns JS et al.: Spl7013 gel as a topical microbicide for prevention of vaginal transmission of sHIV89.6p in macaques. AIDS Res. Hum. Retroviruses21(3),207–213 (2005).
  Medline CASGoogle Scholar
• 139  Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC: Targeted delivery of psc-rantes for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res.26(3),502–511 (2009).
  Medline CASGoogle Scholar
• 140  Lederman MM, Veazey RS, Offord R et al.: Prevention of vaginal sHIV transmission in rhesus macaques through inhibition of ccr5. Science306(5695),485–487 (2004).
  Medline CASGoogle Scholar
• 141  Palliser D, Chowdhury D, Wang QY et al.: An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature439(7072),89–94 (2006).
  Medline CASGoogle Scholar
• 142  Rossi JJ: Topical antiviral siRNA: A practical siRNA microbicide? Gene Ther.13(21),1493–1494 (2006).
  Medline CASGoogle Scholar
• 143  Wu Y, Navarro F, Lal A et al.: Durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell. Host Microbe5(1),84–94 (2009).
  Medline CASGoogle Scholar
• 144  Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM: Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat. Mater.8(6),526–533 (2009).
  Medline CASGoogle Scholar
• 145  Zhang LF, Chan JM, Gu FX et al.: Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano2(8),1696–1702 (2008).
  Medline CASGoogle Scholar
• 146  Zhang LF, Radovic-Moreno AF, Alexis F et al.: Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. Chem. Med. Chem.2(9),1268–1271 (2007).
  CASGoogle Scholar
• 147  Wang Y, Gao SJ, Ye WH, Yoon HS, Yang YY: Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater.5(10),791–796 (2006).
  Medline CASGoogle Scholar
• 148  Lee ALZ, Wang Y, Cheng HY, Pervaiz S, Yang YY: The co-delivery of paclitaxel and herceptin using cationic micellar nanoparticles. Biomaterials30(5),919–927 (2009).
  Medline CASGoogle Scholar
• 149  Shacklett BL: Can the new humanized mouse model give HIV research a boost. PLoS Med.5(1),e13 (2008).
  MedlineGoogle Scholar
• 150  Shultz LD, Ishikawa F, Greiner DL: Humanized mice in translational biomedical research. Nat. Rev. Immunol.7(2),118–130 (2007).
  Medline CASGoogle Scholar
• 151  Damge C, Reis CP, Maincent P: Nanoparticle strategies for the oral delivery of insulin. Expert Opin. Drug Del.5(1),45–68 (2008).
  Medline CASGoogle Scholar
• 152  Lai SK, Wang YY, Hanes J: Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Del. Rev.61(2),158–171 (2009).
  Medline CASGoogle Scholar
• 153  Tang BC, Dawson M, Lai SK et al.: Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl Acad. Sci. USA106(46),19268–19273 (2009).
  Medline CASGoogle Scholar
• 154  Xing JF, Deng LD, Li J, Dong AJ: Amphiphilic poly{[α-maleic anhydride-omega-methoxy-poly(ethylene glycol)]-co-(ethyl cyanoacrylate)} graft copolymer nanoparticles as carriers for transdermal drug delivery. Int. J. Nanomedicine4,227–232 (2009).
  Medline CASGoogle Scholar